DAFNA Capital Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
DAFNA Capital Management reported a $524M portfolio of 88 positions to the SEC as of the end of Q2 2026. Its largest positions are RVMD, XBI, CMPS.
Sections with a free account
What changed this quarter
61 positions with a change (12 new, 18 added to, 25 trimmed, 6 sold); also, 2 entered through an IPO, 2 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- State Street SPDR S&P Biotech ETF−38%fewer sharesReduced9.4% → 5.9%
- Denali Therapeutics+132%more sharesIncreased1.4% → 3.6%
- Nektar Therapeutics+93%more sharesIncreased2.7% → 4.2%
- Insulet+469%more sharesIncreased0.5% → 1.8%
- Biohaven−84%fewer sharesReduced1.6% → 0.4%
- Ascendis Pharma A/S+109%more sharesIncreased1.2% → 2.5%
- COMPASS Pathways−17%fewer sharesReduced3.1% → 5.4%
- MBX Biosciences−93%fewer sharesReduced1.2% → 0.1%
- Edgewise Therapeutics+102%more sharesIncreased0.8% → 1.8%
- Bicara Therapeutics−32%fewer sharesReduced1.9% → 1.6%
- Cytokinetics−21%fewer sharesReduced3.3% → 2.8%
- iShares Biotechnology ETF−31%fewer sharesReduced2.4% → 1.5%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Revolution MedicinesRVMD20.1%
- State Street SPDR S&P Biotech ETFXBI5.9%
- COMPASS PathwaysCMPS5.4%
- StereotaxisSTXS4.5%
- Nektar TherapeuticsNKTR4.2%
- Denali TherapeuticsDNLI3.6%
- IDEAYA BiosciencesIDYA3.5%
- AtriCureATRC3.2%
- Xenon PharmaceuticalsXENE2.9%
- CytokineticsCYTK2.8%
- Arcus BiosciencesRCUS2.6%
- Ascendis Pharma A/SASND2.5%
- Neurocrine BiosciencesNBIX1.9%
- AxogenAXGN1.8%
- InsuletPODD1.8%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 93%
- ● No sector 7%
How its portfolio changed (8 quarters)
Q2 2026: 88
Q2 2026: 56%
Q2 2026: 13.1%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 30, 2026 (high confidence).
The data, as reported: DAFNA CAPITAL MANAGEMENT, LLC (CRD 129053): 7.B private funds: 6 hedge (gross assets $1.3 bn); 5.D assets by client type: pooled vehicles 100% (of $645M)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Stieven Capital AdvisorsInvestment firm · $524M
- Artia Global PartnersInvestment firm · $526M
- Unio CapitalInvestment firm · $526M
- Webs Creek Capital ManagementInvestment firm · $528M
- Palo Duro Investment PartnersInvestment firm · $518M
- Manitou Investment ManagementInvestment firm · $532M